Tatva Chintan Pharma Q3 Review - Weak Margins On Subdued Topline Performance; Long-Term Play Intact: KRChoksey

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..KRChoksey Research Report.Tatva Chintan Pharma Chem Ltd.'s revenue stood at Rs 1,047 million down by 15.3% QoQ on account of contraction in demand witnessed for its product segment ‘Structured Directing Agents’ that contributed 51% of revenue as against 62% in the previous quarter. Ebitda stood at Rs 238 million, de-grew by down 2.9% YoY due to increased cost of sales by 40% YoY accompanied by rise in other expenses by 68% YoY. As a result, Ebitda margin declined to 22.75% versus 30.6% in Q3 FY21. Profit after tax grew by 9.2% YoY at Rs 228 million. Profit after tax margin reported at 21.8% declined by 427 bps YoY / 443 bps QoQ. Tatva Chintan Pharma’s nine months-FY22 performance posted strong growth in revenue, Ebitda and profit after tax at 75% / 107% / 152% on YoY basis, respectively. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Tatva Chintan Pharma Q3 Review - Weak Margins On Subdued Topline Performance; Long-Term Play Intact: KRChoksey

Tatva Chintan Pharma Q3 Review - Weak Margins On Subdued Topline Performance; Long-Term Play Intact: KRChoksey

Choose a plan